These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 27718182)

  • 1. Overview of Vaccine Adjuvants: Introduction, History, and Current Status.
    Shah RR; Hassett KJ; Brito LA
    Methods Mol Biol; 2017; 1494():1-13. PubMed ID: 27718182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designing and building the next generation of improved vaccine adjuvants.
    Brito LA; O'Hagan DT
    J Control Release; 2014 Sep; 190():563-79. PubMed ID: 24998942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine adjuvants: current state and future trends.
    Petrovsky N; Aguilar JC
    Immunol Cell Biol; 2004 Oct; 82(5):488-96. PubMed ID: 15479434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Particulate inorganic adjuvants: recent developments and future outlook.
    Maughan CN; Preston SG; Williams GR
    J Pharm Pharmacol; 2015 Mar; 67(3):426-49. PubMed ID: 25496339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New developments in vaccine research--unveiling the secret of vaccine adjuvants.
    de Veer M; Meeusen E
    Discov Med; 2011 Sep; 12(64):195-204. PubMed ID: 21955847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of size on particulate vaccine adjuvants.
    Shah RR; O'Hagan DT; Amiji MM; Brito LA
    Nanomedicine (Lond); 2014 Dec; 9(17):2671-81. PubMed ID: 25529570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic adjuvants for modern vaccine formulations.
    Vogel FR
    Ann N Y Acad Sci; 1995 May; 754():153-60. PubMed ID: 7625649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Quo vadis in vaccines: From the empirical approach to the new wave of technology].
    Fernández-Prada M; López Trigo JA; Bayas JM; Cambronero MDR
    Rev Esp Geriatr Gerontol; 2020; 55(3):160-168. PubMed ID: 32014265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbohydrate-based vaccine adjuvants - discovery and development.
    Hu J; Qiu L; Wang X; Zou X; Lu M; Yin J
    Expert Opin Drug Discov; 2015 Oct; 10(10):1133-44. PubMed ID: 26372693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvants: Classification, Modus Operandi, and Licensing.
    Apostólico Jde S; Lunardelli VA; Coirada FC; Boscardin SB; Rosa DS
    J Immunol Res; 2016; 2016():1459394. PubMed ID: 27274998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aluminium compounds for use in vaccines.
    Lindblad EB
    Immunol Cell Biol; 2004 Oct; 82(5):497-505. PubMed ID: 15479435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An overview of adjuvants utilized in prophylactic vaccine formulation as immunomodulators.
    Chauhan N; Tiwari S; Iype T; Jain U
    Expert Rev Vaccines; 2017 May; 16(5):491-502. PubMed ID: 28285554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine technologies: From whole organisms to rationally designed protein assemblies.
    Karch CP; Burkhard P
    Biochem Pharmacol; 2016 Nov; 120():1-14. PubMed ID: 27157411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Army Liposome Formulation (ALF) family of vaccine adjuvants.
    Alving CR; Peachman KK; Matyas GR; Rao M; Beck Z
    Expert Rev Vaccines; 2020 Mar; 19(3):279-292. PubMed ID: 32228108
    [No Abstract]   [Full Text] [Related]  

  • 15. History of vaccines and positioning of current trends.
    Payette PJ; Davis HL
    Curr Drug Targets Infect Disord; 2001 Nov; 1(3):241-7. PubMed ID: 12455398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of vaccines: how the past led to the future.
    Plotkin SA; Plotkin SL
    Nat Rev Microbiol; 2011 Oct; 9(12):889-93. PubMed ID: 21963800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens.
    Singh M; Ugozzoli M; Kazzaz J; Chesko J; Soenawan E; Mannucci D; Titta F; Contorni M; Volpini G; Del Guidice G; O'Hagan DT
    Vaccine; 2006 Mar; 24(10):1680-6. PubMed ID: 16300864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer vaccine adjuvants--recent clinical progress and future perspectives.
    Banday AH; Jeelani S; Hruby VJ
    Immunopharmacol Immunotoxicol; 2015 Feb; 37(1):1-11. PubMed ID: 25318595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smart adjuvants.
    Schmidt CS; Morrow WJ; Sheikh NA
    Expert Rev Vaccines; 2007 Jun; 6(3):391-400. PubMed ID: 17542754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New generation adjuvants--from empiricism to rational design.
    O'Hagan DT; Fox CB
    Vaccine; 2015 Jun; 33 Suppl 2():B14-20. PubMed ID: 26022561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.